Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Table 13 Change in HbA1c % before and after autologous bone marrow derived stem cell therapy in Group I

Patient	Baseline	3 mo	6 mo	12 mo	18 mo	24 mo
1	7.2	5.7	7.1	6.4	6.8	7.3
2	6.7	6.2	6.7	6.9	6	-
3	6	-	6.4	5.7	-	-
4	7	6.8	6.6	-	-	-
5	6.1	6.3	5.9	-	-	-
6	6.9	6.5	6.4	-	-	-
7	Lost to FU
Mean ± SE	6.8 ± 0.18	6.3 ± 0.18	6.5 ± 0.16
P value		0.164	0.355